1. Academic Validation
  2. Discovery of Fused Isoquinolinone/Triazole as a Scaffold for Tankyrase and PARP Inhibition

Discovery of Fused Isoquinolinone/Triazole as a Scaffold for Tankyrase and PARP Inhibition

  • J Med Chem. 2026 Jan 8;69(1):330-351. doi: 10.1021/acs.jmedchem.5c02481.
Konstantinos A Ouzounthanasis 1 Chiara Bosetti 2 Juho Alaviuhkola 2 Saurabh S Dhakar 2 Christiana Mantzourani 3 Maroula G Kokotou 3 Demetrios Kanetidis 1 Lari Lehtiö 2 Alexandros E Koumbis 1
Affiliations

Affiliations

  • 1 Laboratory of Organic Chemistry, Department of Chemistry, Aristotle University, 54124 Thessaloniki, Greece.
  • 2 Faculty of Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, 90220 Oulu, Finland.
  • 3 Laboratory of Chemistry, Department of Food Science and Human Nutrition, Agricultural University of Athens, 11855 Athens, Greece.
Abstract

A series of fused isoquinolinone/triazole hybrids were designed and prepared applying a unified versatile synthetic strategy. This practically involved three steps, a novel one-pot CuAAc "click" reaction-iodination process, an amidation and a copper-catalyzed intramolecular Ullmann cyclization and was found to be applicable for a variety of substitutions patterns on the main framework. Some of those synthesized hybrids were tested for selected ADP-ribosyltransferases and found to display nanomolar potency against TNKS2, whereas selectivity was also observed in comparison to Other tested PARPs. The SAR studies divulged key structural features which are responsible for this selectivity. Moreover, the identification of the binding site of those selective derivatives using X-ray crystallography revealed that they are accommodated in the nicotinamide binding subsite while certain groups extend toward a hydrophobic pocket unique to tankyrases.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-180926
    PARP10抑制剂